CN105492454B - 合成针对1型肺炎链球菌的疫苗 - Google Patents

合成针对1型肺炎链球菌的疫苗 Download PDF

Info

Publication number
CN105492454B
CN105492454B CN201480046993.4A CN201480046993A CN105492454B CN 105492454 B CN105492454 B CN 105492454B CN 201480046993 A CN201480046993 A CN 201480046993A CN 105492454 B CN105492454 B CN 105492454B
Authority
CN
China
Prior art keywords
compound
general formula
defined above
galap
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480046993.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105492454A (zh
Inventor
P·H·希伯格
C·L·派瑞拉
C·安妮施
B·舒曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13183826.0A external-priority patent/EP2845860A1/en
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of CN105492454A publication Critical patent/CN105492454A/zh
Application granted granted Critical
Publication of CN105492454B publication Critical patent/CN105492454B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G01N2333/3156—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae [Pneumococcus]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201480046993.4A 2013-07-07 2014-07-07 合成针对1型肺炎链球菌的疫苗 Active CN105492454B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13175447 2013-07-07
EP13175447.5 2013-07-07
EP13183826.0A EP2845860A1 (en) 2013-09-10 2013-09-10 Synthetic vaccines against Streptococcus pneumoniae
EP13183826.0 2013-10-09
EP13196568.3 2013-10-12
EP13196568 2013-12-10
PCT/EP2014/064407 WO2015004041A1 (en) 2013-07-07 2014-07-07 Synthetic vaccines against streptococcus pneumoniae type 1

Publications (2)

Publication Number Publication Date
CN105492454A CN105492454A (zh) 2016-04-13
CN105492454B true CN105492454B (zh) 2019-09-27

Family

ID=51257468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480046993.4A Active CN105492454B (zh) 2013-07-07 2014-07-07 合成针对1型肺炎链球菌的疫苗

Country Status (15)

Country Link
US (1) US10328141B2 (enExample)
EP (1) EP3019513B1 (enExample)
JP (1) JP6416249B2 (enExample)
KR (1) KR102250099B1 (enExample)
CN (1) CN105492454B (enExample)
AU (1) AU2014289342B2 (enExample)
BR (1) BR112016000210A2 (enExample)
CA (1) CA2917365A1 (enExample)
HK (1) HK1224300A1 (enExample)
IL (1) IL243452B (enExample)
MX (1) MX2016000099A (enExample)
RU (1) RU2016103771A (enExample)
SG (1) SG11201600042YA (enExample)
WO (1) WO2015004041A1 (enExample)
ZA (1) ZA201600136B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10188718B2 (en) * 2014-12-12 2019-01-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against Streptococcus pneumoniae serotype 4
US20190119313A1 (en) * 2016-04-14 2019-04-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Improved preparation of vaccines against streptococcus pneumoniae type 3
WO2019018251A1 (en) 2017-07-17 2019-01-24 3M Innovative Properties Company BEND LIMIT FILM
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060294A (zh) * 1990-09-28 1992-04-15 美国氰胺公司 改良的寡糖结合菌苗
EP0497525A2 (en) * 1991-01-28 1992-08-05 Merck & Co. Inc. Pneumococcal polysaccharide conjugate vaccine
CN1449293A (zh) * 2000-06-29 2003-10-15 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
WO2006120576A2 (en) * 2005-05-06 2006-11-16 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-a vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
US20130116423A1 (en) 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2011137181A1 (en) 2010-04-27 2011-11-03 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for moraxella vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060294A (zh) * 1990-09-28 1992-04-15 美国氰胺公司 改良的寡糖结合菌苗
EP0497525A2 (en) * 1991-01-28 1992-08-05 Merck & Co. Inc. Pneumococcal polysaccharide conjugate vaccine
CN1449293A (zh) * 2000-06-29 2003-10-15 史密丝克莱恩比彻姆生物有限公司 多价疫苗组合物
WO2006120576A2 (en) * 2005-05-06 2006-11-16 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-a vaccines

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Alphert E. Christina,等.Galacturonic Acid Lactones in the Synthesis of All Trisaccharide Repeating Units of the Zwitterionic Polysaccharide Sp1.《J. Org. Chem.》.2011,第76卷第1692-1706页. *
Galacturonic Acid Lactones in the Synthesis of All Trisaccharide Repeating Units of the Zwitterionic Polysaccharide Sp1;Alphert E. Christina,等;《J. Org. Chem.》;20110222;第76卷;第1692-1706页 *
On the Emerging Role of Chemistry in the Fashioning of Biologics: Synthesis of a Bidomainal Fucosyl GM1-Based Vaccine for the Treatment of Small Cell Lung Cancer;Pavel Nagorny，等;《J. Org. Chem.》;20090807;第74卷(第15期);第5157-5162页 *
On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines;Govindaswami Ragupathi，等;《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES》;20021015;第99卷(第21期);第13699-13704页 *
Synthesis of Monomeric and Dimeric Repeating Units of the Zwitterionic Type 1 Capsular Polysaccharide from Streptococcus pneumoniae;Xiangyang Wu,等;《Chem. Eur. J.》;20100315;第16卷(第11期);第3476-3488页 *
The Immunogenicity of the Tumor-Associated Antigen Lewisy May Be Suppressed by a Bifunctional Cross-Linker Required for Coupling to a Carrier Protein;Therese Buskas，等;《Chem. Eur. J.》;20040719;第19卷(第14期);第3517-3524页 *
Uronic Acids in Oligosaccharide Synthesis;Leendert J. van den Bos,等;《Eur. J. Org. Chem.》;20070801;第2007卷(第24期);第3963–3976页 *
Xiangyang Wu,等.Synthesis of Monomeric and Dimeric Repeating Units of the Zwitterionic Type 1 Capsular Polysaccharide from Streptococcus pneumoniae.《Chem. Eur. J.》.2010,第16卷(第11期),第3476-3488页. *

Also Published As

Publication number Publication date
KR20160029844A (ko) 2016-03-15
AU2014289342A1 (en) 2016-01-28
EP3019513A1 (en) 2016-05-18
US10328141B2 (en) 2019-06-25
JP6416249B2 (ja) 2018-10-31
JP2016526564A (ja) 2016-09-05
SG11201600042YA (en) 2016-02-26
HK1224300A1 (zh) 2017-08-18
EP3019513B1 (en) 2018-01-17
CN105492454A (zh) 2016-04-13
ZA201600136B (en) 2017-04-26
CA2917365A1 (en) 2015-01-15
KR102250099B1 (ko) 2021-05-10
WO2015004041A1 (en) 2015-01-15
AU2014289342B2 (en) 2018-05-31
IL243452B (en) 2019-02-28
RU2016103771A (ru) 2017-08-11
MX2016000099A (es) 2016-07-07
BR112016000210A2 (pt) 2017-08-22
US20160346374A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CN105492454B (zh) 合成针对1型肺炎链球菌的疫苗
CN106879257B (zh) 针对肺炎链球菌(Streptococcus pneumoniae)血清型8的疫苗
CN111448205B (zh) 抗肺炎克雷伯菌的疫苗
CN111448204B (zh) 抗肺炎克雷伯菌的疫苗
JP2016530212A (ja) ストレプトコッカス ニューモニエ３型に対するタンパク質およびペプチドフリーの合成ワクチン
CN107709343B (zh) 针对肺炎链球菌血清型5的疫苗
CN108367059B (zh) 针对肺炎链球菌血清型2的合成疫苗
US20140234364A1 (en) Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis
HK1256630A1 (en) Synthetic vaccines against streptococcus pneumoniae serotype 2
EP2845860A1 (en) Synthetic vaccines against Streptococcus pneumoniae
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant